Evidence map›Paper›PMID 36354434›Full record

ArticleBiosensors2022

A Molecular Lateral Flow Assay for SARS-CoV-2 Quantitative Detection.

Panagiotis Maglaras, Ioannis Lilis, Fotini Paliogianni, Vasiliki Bravou, Despina P Kalogianni

Open access · goldAbstract read
In one paragraph

Article in Biosensors, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Design of a lateral flow assay targeting the conserved NIID_2019-nCoV_N gene region for molecular viral diagnosis.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2025
    Article
  4. Article
  5. Carrageenan fromBiosensors · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Panagiotis MaglarasDepartment of Chemistry, University of Patras, 26504 Rio, Patras, Greece.
Ioannis LilisDepartment of Physiology, Faculty of Medicine, University of Patras, 26504 Rio, Patras, Greece.
Fotini PaliogianniDepartment of Microbiology, Medical School, University of Patras, 26504 Rio, Patras, Greece.
Vasiliki BravouDepartment of Anatomy-Histology-Embryology, Medical School, University of Patras, 26504 Rio, Patras, Greece.ORCID 0000-0002-4635-0204
Despina P KalogianniDepartment of Chemistry, University of Patras, 26504 Rio, Patras, Greece.ORCID 0000-0001-9638-8713
University of Patras · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the onset of the SARS-CoV-2 pandemic, several COVID-19 detection methods, both commercially available and in the lab, have been developed using different biomolecules as analytes and different detection and sampling methods with high analytical performance. Developing novel COVID-19 detection assays is an exciting research field, as rapid accurate diagnosis is a valuable tool to control the current pandemic, and also because the acquired knowledge can be deployed for facing future infectious outbreaks. We here developed a novel gold-nanoparticle-based nucleic acid lateral flow assay for the rapid, visual, and quantitative detection of SARS-CoV-2. Our method was based on the use of a DNA internal standard (competitor) for quantification and involved RT-PCR, the hybridization of biotinylated PCR products to specific oligonucleotide probes, and detection with a dual lateral flow assay using gold nanoparticles conjugated to an anti-biotin antibody as reporters. The developed test allowed for rapid detection by the naked eye and the simultaneous quantification of SARS-CoV-2 in nasopharyngeal swabs with high specificity, detectability, and repeatability. This novel molecular strip test for COVID-19 detection represents a simple, cost-effective, and accurate rapid test that is very promising to be used as a future diagnostic tool.

Indexed as

COVID-19Metal NanoparticlesGoldHumansPandemicsSARS-CoV-2Sensitivity and SpecificityGoldcoronavirusCOVID-19gold nanoparticlesinternal standardrapid teststrip

Identifiers

PMID36354434
PMCPMC9687750
OpenAlexW4307290866

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.